Insulin resistance and sustained virological response in hepatitis C: From bench to bedside

Liver International

Volumn 31, Issue 1, 2011, Pages 1-3

  Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

EDITORIAL; HEPATITIS C; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HEALTH STATUS INDICATORS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78650148944     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02365.x     Document Type: Editorial

References (20)

1. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol 2008; 102: 5L-9L.
2. Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29 (Suppl. 2): 3-12.
3. Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010. DOI: DOI: 10.1136/gut.2010.219089 [Epub ahead of print]
4. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
5. Pazienza V, Clément S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-71.
6. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-44.
7. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-44.
8. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-7.
9. Romero-Gómez M, Del Mar Viloria M, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
10. Fattovich G, Covolo L, Pasino M, et al. The homeostasis model of assessment of insulin resistance score is not predictive of sustained virological response in chronic hepatitis C patients. Liver Int 2010. DOI: DOI: 10.1111/j.1478-3231.2010.02343.x [Epub ahead of print]
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
12. Miller WG, Thienpont LM, Insulin Standardization Work Group et al. Toward standardization of insulin immunoassays. Clin Chem 2009; 55: 1011-8.
13. Staten MA, Stern MP, Insulin Standardization Work Group et al. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 2010; 33: 205-6.
14. Heinemann L. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care: response to Staten et al. Diabetes Care 2010; 33: e83.
15. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-8.
16. Mizuta T, Kawaguchi Y, Eguchi Y, et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010; 55: 183-9.
17. Honda M, Sakai A, Hokuriku Liver Study Group et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
18. Del Campo JA, Romero-Gómez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol 2009; 15: 5014-9.
19. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-77.
20. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29 (Suppl. 2): 26-37.